Avalo Therapeutics, Inc.

AVTXNASDAQHealthcare● Active

$14.76

+$1.09(+7.97%)

Market Cap$166701167

P/E Ratio—

52W High$24.27

52W Low$4.46

Avg Volume1.6M

Open$14.02

Beta0.82

Free Cash Flow Financials Revenue

Avalo Therapeutics, Inc. (AVTX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

AVTX · free cash flow · updated Jun 15, 2026

Core FCF metrics

AVTX · FCF · TTM · margin & CAGR

Free cash flow was −$51.5M for FY2025 (fiscal year ending 2025-12-31), down 4.9% year-over-year

FY2025 Free Cash Flow−$51.5M▼ -4.9% YoY

Trailing 12M (TTM)−$59.7Mtrailing 4 quarters sum

FCF Margin< −999%−$51.5M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

AVTX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$51.5M(0M)−$51.5M▼ 4.9%—

FY2024−$49.1M(0M)−$49.1M▼ 59.1%—

FY2023−$30.7M(0M)−$30.8M▼ 14.9%—

FY2022−$26.8M(0M)−$26.8M▲ +62.2%-148.7%

FY2021−$70.9M(0M)−$71.0M▼ 74.9%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

AVTX · P/FCF · FCF yield · FCF per share

Avalo Therapeutics, Inc. (AVTX) reported negative free cash flow of −$0.05B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

AVTX · cash flow statement · operating / investing / financing

For FY2025, Avalo Therapeutics, Inc. generated −$51.5M in operating cash flow and spent 0M in capital expenditures, yielding −$51.5M in free cash flow.

Operating Activities

−$51.5M

Cash from core business operations

2025-12-31

Investing Activities

−$81.7M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$14.6M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$51.5M) − |CapEx| (0M) = FCF (−$51.5M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

AVTX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Avalo Therapeutics, Inc.YOU

AVTX

−$51.5M-4.9%-87216.9%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Avalo Therapeutics, Inc. (AVTX) reported free cash flow of −$51.5M for FY2025 (fiscal year ending 2025-12-31), down 4.9% year-over-year.

Based on available data, Avalo Therapeutics, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $12.5M in FY2017.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

AVTX free cash flow · 8 questions

Avalo Therapeutics, Inc. free cash flow was −$51.5M for FY2025, down 4.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$59.7M.

AVTX free cash flowAVTX FCFAVTX FCF 2025AVTX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Avalo Therapeutics, Inc. · Avalo Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026